Skip to main content
. Author manuscript; available in PMC: 2010 Nov 15.
Published in final edited form as: J Immunol. 2009 Oct 21;183(10):6588–6599. doi: 10.4049/jimmunol.0902029

Figure 9. Effect of MAP kinase inhibitors on phagocytosis and maturation of DCs.

Figure 9

DCs were treated with the p38 inhibitor SB203580 (SB), the ERK1/2 inhibitors UO126 (U), PD98059 (PD), the JNK inhibitor SP600125 (SP) or with a combination (SB+U+PD+SP) for 1 h and then incubated with bacteria. Percentage intracellular bacteria were assessed using gentamicin protection assay as described in material and methods section (A). Furthermore, bacteria treated with these MAP kinase inhibitors were stimulated with LPS for 24 and 48 h and expression of maturation markers CD40 (B), HLA-DR (C) and CD86 (D) was assessed using flow cytometry. The data is presented as geometric mean fluorescence intensity (MFI) of logarithmic data subtracted from isotype matched controls. The error bars represent standard deviations of triplicate samples from four individual experiments. The decrease in the expression of maturation markers in DCs pretreated with various inhibitors was significantly lower compared to LPS pretreated cells, *p<0.001 calculated by Student’s t test.